<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35234201</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1536-0229</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>47</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Clinical nuclear medicine</Title>
          <ISOAbbreviation>Clin Nucl Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Solitary Lymph Node Metastasis From a Malignant Peripheral Nerve Sheath Tumor of the Thoracic Vertebra Revealed on FDG PET/CT.</ArticleTitle>
        <Pagination>
          <StartPage>e419</StartPage>
          <EndPage>e420</EndPage>
          <MedlinePgn>e419-e420</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/RLU.0000000000004111</ELocationID>
        <Abstract>
          <AbstractText>Malignant peripheral nerve sheath tumors (MPNSTs) of bone are rare. It is mainly located in the appendicular skeleton. The lung is the most common site of metastasis. Solitary lymph node metastasis is very rare. Herein, we report the imaging findings of MPNST in the first thoracic vertebra with lymph node metastasis in the left axillary region. On FDG PET/CT, these lesions had intense FDG uptake. This case highlights that solitary lytic thoracic vertebral lesion with intense FDG accumulation should regard MPNST as a differential diagnosis and that FDG PET/CT has an important role in the initial staging of MPNST.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Liu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yuhao</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Clin Nucl Med</MedlineTA>
        <NlmUniqueID>7611109</NlmUniqueID>
        <ISSNLinking>0363-9762</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0Z5B2CJX4D</RegistryNumber>
          <NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019788" MajorTopicYN="Y">Fluorodeoxyglucose F18</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018319" MajorTopicYN="Y">Neurofibrosarcoma</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013904" MajorTopicYN="N">Thoracic Vertebrae</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Conflicts of interest and sources of funding: none declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>2</Day>
          <Hour>8</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35234201</ArticleId>
        <ArticleId IdType="doi">10.1097/RLU.0000000000004111</ArticleId>
        <ArticleId IdType="pii">00003072-900000000-95661</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Berkeley R, Andrei V, Saifuddin A. The rare primary bone sarcomas: imaging-pathological correlation. Skeletal Radiol. 2021;50:1491–1511.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu W, Zhang S, Liu J, et al. Intraosseous malignant peripheral nerve sheath tumor of 2 consecutive lumbar vertebrae: a case report and literature review. World Neurosurg. 2019;130:459–466.</Citation>
        </Reference>
        <Reference>
          <Citation>Muthusamy S, Conway SA, Pitcher JD, et al. Primary intraosseous malignant peripheral nerve sheath tumor of the medial cuneiform: a case report and review of the literature. J Foot Ankle Surg. 2017;56:129–134.</Citation>
        </Reference>
        <Reference>
          <Citation>Kendi TK, Erakar A, Yildiz HY, et al. Intraosseous malignant peripheral nerve sheath tumor with local recurrence, lung metastases and death. Skeletal Radiol. 2004;33:223–225.</Citation>
        </Reference>
        <Reference>
          <Citation>Tripathy S, Passah A, Singhal A, et al. Malignant peripheral nerve sheath tumor with bilateral adrenal metastases: role of 18F-FDG PET/CT in response assessment to tyrosine kinase inhibitor and liposomal doxorubicin. Clin Nucl Med. 2019;44:494–495.</Citation>
        </Reference>
        <Reference>
          <Citation>Shen G, Su M, Liu B, et al. PET/CT imaging for solitary primary bone lymphoma of thoracic vertebra. Clin Nucl Med. 2018;43:857–859.</Citation>
        </Reference>
        <Reference>
          <Citation>Li GN, Xiao L, Li L. 18 F-FDG PET/CT imaging in a patient with solitary primary sacral lymphoma. Hell J Nucl Med. 2020;23:356–357.</Citation>
        </Reference>
        <Reference>
          <Citation>Miyazawa N, Ishigame K, Kato S, et al. Thoracic chordoma: review and role of FDG-PET. J Neurosurg Sci. 2008;52:117–121, 121–122.</Citation>
        </Reference>
        <Reference>
          <Citation>Yang G, Wang Z, Liu S, et al. A rare case of urachal carcinoma metastatic to thoracic vertebra detected by FDG PET/CT. Clin Nucl Med. 2017;42:544–546.</Citation>
        </Reference>
        <Reference>
          <Citation>Yanagisawa F, Amano Y, Omori Y, et al. Epithelioid hemangioma of vertebra mimicking metastasis on FDG PET/CT in a patient with renal cell cancer. Clin Nucl Med. 2021;46:148–150.</Citation>
        </Reference>
        <Reference>
          <Citation>Shen G, Ma H, Pan L, et al. Diffuse-type tenosynovial giant cell tumor of the thoracic spine: appearance on FDG PET/CT. Clin Nucl Med. 2019;44:e477–e478.</Citation>
        </Reference>
        <Reference>
          <Citation>Chua SC, O'Connor SR, Wong WL, et al. Case report: solitary plasmacytoma of bone with oncogenic osteomalacia: recurrence of tumour confirmed by PET/CT. A case report with a review of the radiological literature. Br J Radiol. 2008;81:e110–e114.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao Q, Bai Y, Dong A, et al. FDG PET/CT in isolated thoracic vertebral Rosai-Dorfman disease. Clin Nucl med. 2022;47:e135–e136.</Citation>
        </Reference>
        <Reference>
          <Citation>Feng H, Tu N, Bu L. Malignant peripheral nerve sheath tumor arising from transplanted kidney assessed by 18F-FDG PET/CT. Clin Nucl Med. 2020;45:905–907.</Citation>
        </Reference>
        <Reference>
          <Citation>Dong A, Zuo C, Wang Y, et al. Enhanced CT and FDG PET/CT in primary malignant peripheral nerve sheath tumor of the uterine cervix. Clin Nucl Med. 2014;39:825–827.</Citation>
        </Reference>
        <Reference>
          <Citation>Chander S, Westphal SM, Zak IT, et al. Retroperitoneal malignant peripheral nerve sheath tumor: evaluation with serial FDG-PET. Clin Nucl Med. 2004;29:415–418.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
